Shares of Biocon Ltd are trading flat after touching a day’s high of Rs 389.05 on 15th December, despite the company saying it has launched its Glucagon-like Peptide-1 (GLP-1) drug-device combination for diabetes and obesity in the Netherlands through its distribution partner, Pharmamedic BV.

Biocon said the drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management.

The launch follows approval from the Medicines Evaluation Board (MEB) of the Netherlands earlier this year. It marks the first EU country where Biocon will directly launch Liraglutide under its own brand.

The company said its integrated manufacturing and delivery capabilities enable it to offer high-quality, affordable treatments at scale.

Separately, Biocon said its subsidiary, Biocon Biologics, has entered into a settlement and licence agreement with Regeneron and Bayer to commercialise the biosimilar Aflibercept globally. The deal covers Europe and the rest of the world, following an earlier settlement for the US and Canada.

With this, Biocon Biologics will commercialise Yesafili, a biosimilar Aflibercept (40 mg/ml), across global markets. Yesafili is used to treat multiple eye-related conditions, the company added.

At 2:00 PM, shares of Biocon were trading 0.35% lower at Rs 385 on NSE.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!